A Study of Stem Cells and Filgrastim

A Pilot Study of Stem Cell Mobilization and Harvesting From the Peripheral Blood Using Filgrastim


Hauptsponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Quelle National Institute of Allergy and Infectious Diseases (NIAID)
Kurze Zusammenfassung

To determine the safety of stem cell harvesting after administration of filgrastim ( G-CSF ) to mobilize bone marrow stem cells into the peripheral blood in patients at various stages of HIV-1 infection as well as in HIV-negative volunteers. To determine the surface phenotypic and functional characteristics as well as the viral load in the stem cells obtained following this procedure.

detaillierte Beschreibung

Patients and volunteers receive seven daily subcutaneous injections of G-CSF. On days 5 and 6 of drug administration, patients have peripheral blood mononuclear cells harvested by leukapheresis. HIV-positive patients are stratified into three cohorts based on CD4 count and presence of symptoms. If no increase in number of harvested stem cells and no grade 4 bone pain toxicity occur in two of the first three patients in a cohort, then the last three patients in that cohort will receive a dose escalation. Patients are followed for 24 weeks.

Gesamtstatus Completed
Fertigstellungstermin October 1998
Phase N/A
Studientyp Interventional
Einschreibung 24

Interventionsart: Drug

Interventionsname: Filgrastim



Inclusion Criteria

Concurrent Medication:


- PCP prophylaxis.

- Antiretroviral therapy in patients with CD4 counts <= 500 cells/mm3.

- Narcotic analgesics for grade 3/4 bone pain toxicity.

Patients must have:

- HIV infection.

- HIV infected patients with CD4 count > 500 cells/mm3 must be asymptomatic. Patients with CD4 count 200-500 cells/mm3 may be either asymptomatic or symptomatic but must not have AIDS. Patients with CD4 count < 200 cells/mm3 may or may not have AIDS-defining conditions.

- No antiretroviral therapy within the past 30 days in patients with asymptomatic disease and CD4 count > 500 cells/mm3.

- Stable antiretroviral therapy for the past 60 days if CD4 count <= 500 cells/mm3.

- Suitable venous access.

Prior Medication:


- Prior antiretroviral therapy.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Current malignancy.

- Any medication condition that interferes with study evaluation.

- Known hypersensitivity to E. coli-derived proteins (e.g., insulin, human growth hormones).

Concurrent Medication:


- Acute treatment for serious opportunistic infection.

- Systemic cytotoxic chemotherapy.

Concurrent Treatment:


- Systemic radiation therapy.

Patients with the following prior conditions are excluded:

- Prior malignancy.

- Leukapheresis or lymphopheresis within the past 180 days.

- Significant active CNS disease or seizures within the past year.

Prior Medication:


- G-CSF or GM-CSF within the past 6 months.

- Investigational antiretrovirals within the past 30 days.

- Treatment for opportunistic infection within the past 14 days.

Active alcohol or substance abuse.

Geschlecht: All

Mindestalter: 18 Years

Maximales Alter: N/A

Gesunde Freiwillige: Accepts Healthy Volunteers

Insgesamt offiziell
UCLA CARE Center CRS | Los Angeles, California, 90095, United States
University of Colorado Hospital CRS | Aurora, Colorado, United States
Standort Länder

United States


May 2012

Verantwortliche Partei

Art: Sponsor

Hat den Zugriff erweitert No
Bedingung Durchsuchen
Studiendesign Info

Hauptzweck: Treatment

Quelle: ClinicalTrials.gov